The Global Fund will donate 5.0 million U.S. dollars to finance the procurement of critical health products for Venezuela, which is in the midst of a severe economic and health crisis.
Donor government disbursements to combat HIV in low- and middle-income countries increased 16 percent from US$7 billion in 2016 to US$8.1 billion in 2017 – though the higher total stems largely from the timing of U.S.
Global Fund multi-country program in East Africa spearheads trip to China to learn about harm reduction technologies
“A Quarter for Prevention”: Study finds Global Fund investments in HIV prevention in Africa fall short
“There is a painful awareness among communities in countries whose economies are growing that donors are pulling out and abandoning them… This [transitioning] process is driven by the criteria donors have laid out for eligibility, and demonstrated by the actual level of disbursements going to some countries. But communities know that growing economies do not equal growing domestic support for communities in the HIV response.”
The Global Fund, one of the main purchasers of generic antiretroviral (ARV) medicines for HIV patients in low- and middle-income countries, has dismissed concerns that the limited number of manufacturers tapped to supply these drugs could result in immediate or future shortages. Fund officials said systems are in place to forecast demand, deal with any supply disruptions and increase production to meet future need.
After initially rejecting a plea for assistance from Venezuelan NGOs out of hand, the Global Fund now says it may be able to help
In an exchange of letters that spanned more than seven months, the Global Fund at first rejected a plea for help from the Venezuelan Network of Positive People (RVG+), but then may have left the door open to providing some assistance via other agencies. This is a story that is still unfolding.
According to the Global Fund, Venezuela is currently not eligible for funding under the Fund’s Eligibility Policy.
The Global Fund has pledged to re-energize HIV prevention and, in line with that commitment, civil society groups are calling on the Fund to offer more explicit data on how much it spends on these efforts. That includes not only overall expenditure data, but also granular information, like spending at a country level and spending on specific interventions.
AHF and researchers call for more transparency in UNAIDS’ estimates of the numbers of people on ARVs
The AIDS Healthcare Foundation (AHF), a Los Angeles-based AIDS service and activist organization with a global reach, has called for more transparency and accountability in the way UNAIDS estimates the number of people living with HIV/AIDS who are on life-saving antiretroviral treatment.